Эндокринопатии и кардиопатии у больных с синдромом Тернера

1. Morgan T. Turner syndrome: diagnosis and management. Am Fam Physician. 2007; 76: 405–10. PMID: 17708142
2. Faienza M.F., Ventura A., Colucci S. Bone fragility in Turner syndrome: mechanisms and prevention strategies. Front Endocrinol (Lausanne). 2016; 7: 34. doi: 10.3389/fendo.2016.00034
3. Wilson C.A., Heinrichs C., Larmore K.A., Craen M., Brown-Dawson J., Shaywitz S., Ross J., Klein K.O. Estradiol levels in girls with Turner’s syndrome compared to normal prepubertal girls as determined by an ultrasensitive assay. J Pediatr Endocrinol Metab. 2003; 16: 91–6. http://dx.doi.org/10.1515/jpem.2003.16.1.91
4. Hagen C.P., Main K.M., Kjaergaard S., Juul A. FSH, LH, inhibin B and estradiol levels in Turner syndrome depend on age and karyotype: longitudinal study of 70 Turner girls with or without spontaneous puberty. Hum Reprod. 2010; 25: 3134–41. doi: 10.1093/humrep/deq291
5. Sowinska-Przepiera E., Andrysiak-Mamos E., Chełstowski K., Adler G. Association between ER-a polymorphisms and bone mineral density in patients with Turner syndrome subjected to estroprogestagen treatment—a pilot study. J Bone Miner Metab. 2011; 29: 484–92. doi: 10.1007/s00774-010-0247-3
6. Vanderschueren D., Venken K., Ophoff J., Bouillon R., Boonen S. Clinical Review: sex steroids and the periosteum-reconsidering the roles of androgens and estrogens in periosteal expansion. J Clin Endocrinol Metab. 2006; 91: 378–82. http://dx.doi.org/10.1210/jc.2005-1766
7. Han T.S., Cadge B., Conway G.S. Hearing impairment and low bone mineral density increase the risk of bone fractures in women with Turner’s syndrome. Clin Endocrinol (Oxf). 2006; 65: 643–7. doi: 10.1111/j.1365-2265.2006.02643.x
8. Suganuma N., Kawai H., Furuhashi M. Serum follicle-stimulating hormone level is a predictor of bone mineral density in patients with hormone replacement therapy. Arch Gynecol Obstet. 2004; 269: 192–5. doi: 10.1007/s00404-003-0532-7
9. Sun L., Peng Y., Sharrow A.C., Iqbal J., Zhang Z., Papachristou D.J., Zaidi S., Zhu L.L. FSH directly regulates bone mass. Cell. 2006; 125: 247–60. doi: 10.1016/j.cell.2006.01.051
10. Nakashima T., Hayashi M., Fukunaga T., Kurata K., Oh-Hora M., Feng J.Q., Bonewald L.F. Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med. 2011; 17: 1231–4. . doi: 10.1038/nm.2452.
11. Iqbal J., Sun L., Kumar T.R., Blair H.C., Zaidi M. Follicle-stimulating hormone stimulates TNF production from immune cells to enhance osteoblast and osteoclast formation. Proc Natl Acad Sci U S A. 2006; 103: 14925–30. doi: 10.1073/pnas.0606805103
12. Balga R., Wetterwald A., Portenier J., Dolder S., Mueller C., Hofstetter W. Tumor necrosis factoralpha: Alternative role as an inhibitor of osteoclast formation in vitro. Bone. 2006; 39: 325–35. doi: 10.1016/j.bone.2006.02.056
13. Faienza M.F., Brunetti G., Ventura A., Piacente L., Messina M.F., De Luca F. Mechanisms of enhanced osteoclastogenesis in girls and young women with Turner’s Syndrome. Bone. 2015; 81: 228–36. doi: 10.1016/j.bone.2015.07.021
14. Cannon J.G., Kraj B., Sloan G. Follicle-stimulating hormone promotes RANK expression on human monocytes. Cytokine. 2011; 53: 141–7. doi: 10.1016/j.cyto.2010.11.011
15. Cicognani A., Pirazzoli P., Nicoletti A., Baronio F., Conti V., Bonetti S. The SHOX gene: a new indication for GH treatment. J Endocrinol Invest. 2010; 33: 15–8. PMID: 21057180
16. Bakalov V.K., Axelrod L., Baron J., Hanton L., Nelson L.M., Reynolds J.C. Selective reduction in cortical bone mineral density in turner syndrome independent of ovarian hormone deficiency. J Clin Endocrinol Metab. 2010; 88: 5717–22. doi: 10.1210/jc.2003-030913
17. Frederiksen A.L., Hansen S., Brixen K., Frost M. Increased cortical area and thickness in the distal radius in subjects with SHOX-gene mutation. Bone. 2014; 69: 23–9. doi: 10.1016/j.bone.2014.09.001
18. Soucek O., Zapletalova J., Zemkova D., Snajderova M., Novotna D., Hirschfeldova K., Plasilova I., Kolouskova S., Rocek M., Hlavka Z. Prepubertal girls with Turner syndrome and children with isolated SHOX deficiency have similar bone geometry at the radius. J Clin Endocrinol Metab. 2013; 98: E1:241–7. doi: 10.1210/jc.2013-1113.
19. Soucek O., Lebl J., Zapletalova J., Novotna D., Plasilova I., Kolouskova S. Bone geometry and volumetric bone density at the radius in patients with isolated SHOX deficiency. Exp Clin Endocrinol Diabetes. 2013; 121: 109–14. doi: 10.1055/s-0032-1333260.
20. Chiovato L., Larizza D., Bendinelli G., Tonacchera M., Marinó M., Mammoli C., Lorini R., Severi F., Pinchera A. Autoimmune hypothyroidism and hyperthyroidism in patients with Turner’s syndrome. Eur J Endocrinol. 1996; 134: 568–75. doi: 10.1530/eje.0.1340568
21. Bianchi I., Lleo A., Gershwin M.E., Invernizzi P. The X chromosome and immune associated genes. J Autoimmun. 2012; 38: J187–92. doi: 10.1016/j.jaut.2011.11.012.
22. Cogni G., Chiovato L. An overview of the pathogenesis of thyroid autoimmunity. Hormones (Athens). 2013; 12(1):19–29. doi: 10.1007/BF03401283
23. Wikiera B., Barg E., Konieczna A., Głab E., Noczyńska A. The prevalence of thyro-peroxidase antibodies and thyroid function in Turner’s syndrome. Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw. 2006; 12: 190–4. PMID: 17020654
24. Lichiardopol C., Mota M., Braicu D., Militaru C., Mixich F. Diabetes mellitus and Turner syndrome. Rom J Intern Med. 2007; 45: 299–304. PMID: 18333365
25. Bakalov V.K., Cheng C., Zhou J., Bondy C.A. X-Chromosome gene dosage and the risk of diabetes in Turner syndrome. J Clin Endocrinol Metab. 2009; 94: 3289–96. doi: 10.1210/jc.2009-0384
26. Zhao L., Guo M., Matsuoka T.A., Artner I., Jarrett H.W., Friedman D. The Islet beta cell-enriched MafA activator is a key regulator of insulin gene transcription. J Biol Chem. 2009; 280: 11887–94. doi: 10.1074/jbc.M409475200
27. Dulac Y., Pienkowski C., Abadir S., Tauber M., Acar P. Cardiovascular abnormalities in Turner’s syndrome: What prevention? Arch Cardiovasc Dis. 2008; 101: 85–90. doi: 10.1016/j.acvd.2008.05.007.
28. Sybert V.P. Cardiovascular malformations and complications in Turner syndrome. Pediatrics. 1998; 101(1): E11. doi: 10.1542/peds.101.1.e11
29. Castelo-Branco C. Management of Turner syndrome in adult life and beyond. Maturitas. 2014; 79: 471–5. doi: 10.1016/j.maturitas.2014.08.011.
30. Mortensen K.H., Hjerrild B.E., Stochholm K., Andersen N.H., Sørensen K.E., Lundorf E., Hørlyck A., Pedersen E.M. .Dilation of the ascending aorta in Turner syndrome – a prospective cardiovascular magnetic resonance study. J Cardiovasc Magn Reson. 2011; 13: 24. doi: 10.1186/1532-429X-13-24.
31. Martin L.J., Ramachandran V., Cripe L.H., Hinton R.B., Andelfinger G., Tabangin M., Shooner K., Keddache M., Benson D.W. Evidence in favor of linkage to human chromosomal regions 18q, 5q and 13q for bicuspid aortic valve and associated cardiovascular malformations. Hum Genet. 2007; 121: 275–84. https://doi.org/10.1007/s00439-006-0316-9
32. McBride K.L., Riley M.F., Zender G.A., Fitzgerald-Butt S.M., Towbin J.A., Belmont J.W., Cole S.E. NOTCH1 mutations in individuals with left ventricular outflow tract malformations reduce ligand-induced signaling. Hum Mol Genet. 2008; 17: 2886–93. doi: 10.1093/hmg/ddn187.
33. O’Brien K.D. Epidemiology and genetics of calcific aortic valve disease. J Invest Med. 2007; 55(6): 284–91. doi: 10.2310/6650.2007.00010.
34. Nigam V., Srivastava D. Notch1 represses osteogenic pathways in aortic valve cells. J Mol Cell Cardiol. 2009; 47(6): 828–34. doi: 10.1016/j.yjmcc.2009.08.008.
35. Foffa I., Ait Alì L., Panesi P., Mariani M., Festa P., Botto N., Vecoli C., Andreassi M.G. Sequencing of NOTCH1, GATA5, TGFBR1 and TGFBR2 genes in familial cases of bicuspid aortic valve. Bmc Med Genet. 2013; 14: 44. doi: 10.1186/1471-2350-14-44.
36. Wolff D.J., Van Dyke D.L., Powell C.M. Laboratory guideline for Turner syndrome. Genet Med. 2010; 12: 52–5. doi: 10.1097/GIM.0b013e3181c684b2.
37. Haber H.P., Ranke M.B. Pelvic ultrasonography in Turner syndrome: standards for uterine and ovarian volume. J Ultrasound Med. 2009; 18: 271–6.doi: 10.7863/jum.1999.18.4.271
38. Marin A., Weir-McCall J.R., Webb D.J., van Beek E.J.R., Mirsadraee S. Imaging of cardiovascular risk in patients with Turner’s syndrome. Clin Radiol. 2015; 70(8): 803–14. doi: 10.1016/j.crad.2015.03.009.
39. Watts N.B., Bilezikian J.P., Camacho P.M., Greenspan S.L., Harris S.T., Hodgson S.F., Kleerekoper M., Luckey M.M., McClung M.R. American association of clinical endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of postmenopausal osteoporosis: executive summary of recommendations. Endocr Pract. 2010; 16: 1016–19.https://doi.org/10.4158/EP.16.6.1016
40. Bondy C.A. Care of girls and women with Тurner Syndrome: A Guideline of the Turner Syndrome Study Group. J Clin Endocrinol Metab. 2007; 92(1): 10–25. doi: 10.1210/jc.2006-1374
41. Gravholt C.H., Andersen N.H., Conway G.S., Dekkers O.M., Geffner M.E., Woelfle J., Backeljauw P.F. Clinical practice guidelines for the care of girls and women with Turner syndrome: proceedings from the 2016 Cincinnati International Turner Syndrome Meeting. Eur J Endocrinol. 2017; 177(3): G1–70. doi: 10.1530/EJE-17-0430.
42. Stephure D.K.; The Canadian Growth Hormone Advisory Committee. Impact of Growth Hormone Supplementation on Adult Height in Turner Syndrome: Results of the Canadian Randomized Controlled Trial. J Clin Endocrinol Metab. 2005; 90(6): 3360–6. doi: 10.1210/jc.2004-2187
43. Baronio F., Mazzanti L., Girtler Y., Lupi F., Longhi S. The influence of GH treatment on glucose homeostasis in girls with turner syndrome: a 7- year study. J Clin Endocrinol Metab. 2017; 102(3): 878–83. doi: 10.1210/jc.2016-3179.
44. Chamberlain J.J., Rhinehart A.S., Shaefer C.J., Neuman A. Diagnosis and management of diabetes: synopsis of the 2016 American diabetes association standards of medical care in diabetes. Ann Intern Med. 2016; 164(8): 542–52. doi: 10.7326/M15-3016
45. Gravholt C.H. Turner syndrome and the heart: cardiovascular complications and treatment strategies. Am J Cardiovasc Drugs. 2002; 2(6): 401–13. doi: 10.2165/00129784-200202060-00005
46. Allybocus Z.A., Wang C., Shi Hr., Wu Qh.Endocrinopathies and cardiopathies in patients with Turner syndrome, Climacteric. 2018; 21(6): 536–41. doi: 10.1080/13697137.2018.1501674.
47. Madriago E., Nguyen T., McFerson M., Larson E.V., Airhart N., Moller J.H., Silberbach M. Frequency and outcomes of cardiac operations and catheter interventions in turner Syndrome. Am J Cardiol. 2012; 110(4): 580–5. doi: 10.1016/j.amjcard.2012.04.036.

Поступила 01.04.2019

Принята в печать 04.10.2019